NCT06424756 Effects of an Antioxidant Supplement on Blood Vessel Health
| NCT ID | NCT06424756 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | University of Georgia |
| Condition | Healthy |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2024-07-01 |
| Primary Completion | 2030-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 60 participants in total. It began in 2024-07-01 with a primary completion date of 2030-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Cardiovascular disease (CVD) is a leading cause of morbidity and mortality worldwide, and the non-Hispanic Black (NHB) population is disproportionately affected. Our research has previously demonstrated that oxidative stress may contribute to reduced vascular function in otherwise healthy NHB adults, potentially predisposing them to the development of hypertension and CVD. This study is designed to examine whether the mitochondria are an important source of oxidative stress-induced vascular dysfunction in healthy NHB adults.
Eligibility Criteria
Inclusion Criteria: * Self-identify as either non-Hispanic Black or non-Hispanic White. * Men and women 18-75 years old. * Non-hypertensive (systolic blood pressure \[SBP\]\<130 and diastolic blood pressure \[DBP\] \<85 mmHg). * Have low density lipoprotein cholesterol \<150mg/dl. * Have HbA1C \<6.0%. Exclusion Criteria: * Rash, skin disease, or disorders of pigmentation (e.g., psoriasis, eczema, vitiligo, or other skin inflammatory skin disorders) * Known skin allergies to latex or adhesives * Smoking and/or use of nicotine-containing products within the past year * Use of illegal/recreational drugs * Generalized kidney disease * Taking chloramphenicol, cholestyramine, medication for seizures, methotrexate, nitrofurantoin, tetracycline, barbiturates, steroids, phenobarbital/phenytoin, orlistat or pyrimethamine * Any current medications which could conceivably alter the cardiovascular control or responses * Diagnosed or suspected metabolic or cardiovascular disease * Current pregnancy or breastfeeding * History of skin or other cancers * Diagnosed or suspected diabetes (HbA1c ≥6.0) * Anybody with narcolepsy or who has been diagnosed with any condition that impairs body temperature regulation.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06424756 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Healthy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06424756 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06424756 currently recruiting?
Yes, NCT06424756 is actively recruiting participants. Contact the research team at stwolf@uga.edu for enrollment information.
Where is the NCT06424756 trial being conducted?
This trial is being conducted at Athens, United States.
Who is sponsoring the NCT06424756 clinical trial?
NCT06424756 is sponsored by University of Georgia. The trial plans to enroll 60 participants.